

February 15, 2019

## **Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer**

*This information is intended to notify the press release issued on February 14 by Bristol-Myers Squibb.  
Please click <https://www.bms.com/media/press-releases.html> for the original press release.*

First paragraph extracted from the original press release:

(PRINCETON, NJ, February 14, 2019) – Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating *Opdivo* (nivolumab) in combination with *Yervoy* (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from an interim analysis of the Phase 2 CheckMate -650 trial showed that among 32 asymptomatic or minimally symptomatic patients whose disease had progressed after second-generation hormone therapy and who had not received chemotherapy (cohort 1), with a median follow-up of 11.9 months, the objective response rate (ORR) was 25%. Additionally, among 30 patients whose disease progressed after taxane-based chemotherapy (cohort 2), with a median follow-up of 13.5 months, the ORR was 10%.

### **About Opdivo**

Opdivo is an anti-PD-1 antibody that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands, and is the first PD-1 immune checkpoint inhibitor approved in Japan all over the world in July 2014. Opdivo is currently approved in more than 65 countries, including the US and European Union, China, and Japan.

In Japan, ONO launched Opdivo for the treatment of unresectable melanoma in September 2014. Thereafter, ONO received an approval for additional indication of unresectable, advanced or recurrent non-small cell lung cancer in December 2015, unresectable or metastatic renal cell cancer in August 2016, relapsed or refractory classical Hodgkin lymphoma in December 2016, recurrent or metastatic head and neck cancer in March 2017, unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy in September 2017, and unresectable advanced or recurrent malignant pleural mesothelioma which has progressed after chemotherapy and adjuvant treatment of melanoma, etc. in August 2018. In addition, ONO is conducting clinical development program including esophageal cancer, esophago-gastric junction cancer, small cell lung cancer, hepatocellular carcinoma, glioblastoma, urothelial cancer, ovarian cancer, biliary tract cancer, etc.

### **Contact:**

ONO PHARMACEUTICAL CO., LTD.  
Corporate Communications  
[public\\_relations@ono.co.jp](mailto:public_relations@ono.co.jp)